Related Experiment Video

Updated: Jul 29, 2026

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles
12:00

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles

Published on: January 22, 2015

12.5K

Surfactant-Free Chitosan/Cellulose Acetate Phthalate Nanoparticles: An Attempt to Solve the Needs of Captopril

Noelia Nieto González1, Guido Cerri2, Jesús Molpeceres3

  • 1PhD Program in Chemical Science and Technology, Department of Chemistry and Pharmacy, University of Sassari, 07100 Sassari, Italy.

Pharmaceuticals (Basel, Switzerland)
|June 24, 2022
PubMed

Insights

Researchers developed novel chitosan/cellulose nanoparticles for pediatric captopril delivery. These nanoparticles offer a stable, non-toxic liquid formulation for treating pediatric hypertension, heart failure, and diabetic nephropathy.

Area of Science:

  • Pharmaceutical Sciences
  • Nanotechnology
  • Pediatric Medicine

Background:

  • The European Medicines Agency highlights the need for pediatric-specific medicinal products.
  • Captopril formulations suitable for children are required for cardiovascular conditions.

Purpose of the Study:

  • To develop a novel liquid nanoparticle formulation of captopril using chitosan and cellulose acetate phthalate.
  • To create an age-appropriate drug delivery system for pediatric hypertension, heart failure, and diabetic nephropathy.

Main Methods:

  • Nanoparticles (NP-C) were prepared via nanoprecipitation without surfactants.
  • Various cellulose to chitosan ratios were evaluated for encapsulation efficiency.
  • Physicochemical properties, stability, drug release, and cytotoxicity were assessed.

Main Results:

  • A 1:3 chitosan concentration yielded high encapsulation efficiency (61.0 ± 6.5%).
  • NP-C nanoparticles were spherical (427.1 ± 32.7 nm) with good stability for 28 days.
  • Significant captopril release (70% in 2h) was observed, with no cytotoxicity on fibroblasts at relevant doses.

Conclusions:

  • Chitosan/cellulose nanoparticles present a promising platform for pediatric captopril delivery.
  • This formulation could be adapted for both solid and liquid dosage forms for pediatric use.

Keywords:
captoprilcellulose acetate phthalatechitosannanoparticlespaediatric diseasepaediatric formulation

More Related Videos

Synthesis and Characterization of Placental Chondroitin Sulfate A plCSA-Targeting Lipid-Polymer Nanoparticles05:55

Synthesis and Characterization of Placental Chondroitin Sulfate A plCSA-Targeting Lipid-Polymer Nanoparticles

Published on: September 18, 2018

8.8K
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

9.0K

Related Concept Videos

Factors Affecting Dissolution: Particle Size and Effective Surface Area01:23

Factors Affecting Dissolution: Particle Size and Effective Surface Area

Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are employed to...
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...